Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer
- 11 September 2020
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 495, 76-88
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
This publication has 38 references indexed in Scilit:
- Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerizationBioorganic & Medicinal Chemistry, 2011
- miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivoOncogene, 2011
- Discovery of Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding Site in Tubulin As Potential Anticancer AgentsJournal of Medicinal Chemistry, 2010
- Drug resistance in metastatic castration-resistant prostate cancerNature Reviews Clinical Oncology, 2010
- Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung CancerCancer Research, 2007
- Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy GroupJournal of Clinical Oncology, 2006
- Preclinical Pharmacology of the Taxanes: Implications of the DifferencesThe Oncologist, 2004
- Microtubules as a target for anticancer drugsNature Reviews Cancer, 2004
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancerExpert Opinion on Pharmacotherapy, 2001